This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Plourde, P. V. Articles by Backeljauw, P. F. Search for Related Content PubMed PubMed Citation Articles by Plourde, P. V. Articles by Backeljauw, P. F.

Safety and Efficacy of Anastrozole for the Treatment of Pubertal Gynecomastia: A Randomized, Double-Blind, Placebo-Controlled Trial

AstraZeneca Pharmaceuticals LP (P.V.P., H.-C.J., P.E.D., S.D.R.), Wilmington, Delaware 19850; Baystate Medical Center-Children’s Hospital (E.O.R.), Springfield, Massachusetts 01199; University of South Florida (B.B.B., F.B.D.), St. Petersburg, Florida 33701; and Cincinnati Children’s Hospital Medical Center (P.F.B.), Cincinnati, Ohio 45229

Address all correspondence and requests for reprints to: Dr. Paul V. Plourde, AstraZeneca Pharmaceuticals LP, Chesapeake 2B-126, 1800 Concord Pike, P.O. Box 15437, Wilmington, Delaware 19850-5437. E-mail: paul.plourde{at}astrazeneca.com.

Pubertal gynecomastia is thought to result from transient imbalances between estrogen and androgen concentrations. Anastrozole (ARIMIDEX), a potent and selective aromatase inhibitor, decreases estrogen and increases testosterone concentrations in pubertal boys. The safety and efficacy of anastrozole for the treatment of pubertal gynecomastia were evaluated. In a randomized, double-blind, placebo-controlled study of 80 boys, aged 11–18 yr, with pubertal gynecomastia that had not reduced over a 3-month interval, subjects received either anastrozole (1 mg) or placebo once daily for 6 months. A response was defined as a 50% or greater reduction in the calculated volume of both breasts combined using ultrasonography measurements. A comparison of response rates was performed using logistic regression analysis. Secondary end points included changes in serum hormone concentrations. The percentage of patients with a response was 38.5% for the anastrozole group and 31.4% for the placebo group (odds ratio, 1.513; 95% confidence interval, 0.496–4.844; P = 0.47). At 6 months, the median percent change in the testosterone/estradiol ratio was 166% for the anastrozole group and 39% for the placebo group. Anastrozole treatment was well tolerated. In patients with pubertal gynecomastia, no significant difference in the percentage of patients with a 50% or greater reduction in total breast volume, as calculated from ultrasonography measurements, was demonstrated between the anastrozole and placebo groups.

This article has been cited by other articles:

				D. I. Shulman, G. L. Francis, M. R. Palmert, E. A. Eugster, and for the Lawson Wilkins Pediatric Endocrine Society Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development Pediatrics, April 1, 2008; 121(4): e975 - e983. [Abstract] [Full Text] [PDF]

				C. B Niewoehner and A. E Schorer Gynaecomastia and breast cancer in men BMJ, March 29, 2008; 336(7646): 709 - 713. [Full Text] [PDF]

				G. D. Braunstein Gynecomastia N. Engl. J. Med., September 20, 2007; 357(12): 1229 - 1237. [Full Text] [PDF]

				S. Diamantopoulos and Y. Bao Gynecomastia and Premature Thelarche: A Guide for Practitioners Pediatr. Rev., September 1, 2007; 28(9): e57 - e68. [Full Text] [PDF]